123 related articles for article (PubMed ID: 10594868)
1. Pharmacokinetic interactions between HIV-protease inhibitors in rats.
Yamaji H; Matsumura Y; Yoshikawa Y; Takada K
Biopharm Drug Dispos; 1999 Jul; 20(5):241-7. PubMed ID: 10594868
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
3. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
4. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
5. Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.
Parker AJ; Houston JB
Drug Metab Dispos; 2008 Jul; 36(7):1375-84. PubMed ID: 18426953
[TBL] [Abstract][Full Text] [Related]
6. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
Klaus BD; Grodesky MJ
Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221
[No Abstract] [Full Text] [Related]
7. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
[TBL] [Abstract][Full Text] [Related]
8. Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.
Shibata N; Gao W; Okamoto H; Kishida T; Iwasaki K; Yoshikawa Y; Takada K
J Pharm Sci; 2002 Mar; 91(3):680-9. PubMed ID: 11920753
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Kuschak D; Mauss S; Schmutz G; Gantke B
Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil does not alter nelfinavir pharmacokinetics.
Bratt G; Ståhle L
Ther Drug Monit; 2003 Apr; 25(2):240-2. PubMed ID: 12657921
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
12. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
Hsu A; Granneman GR; Bertz RJ
Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
14. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
15. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
Ye ZW; Camus S; Augustijns P; Annaert P
Biopharm Drug Dispos; 2010 Mar; 31(2-3):178-88. PubMed ID: 20238377
[TBL] [Abstract][Full Text] [Related]
16. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell line HT-29/B6.
Bode H; Schmidt W; Schulzke JD; Fromm M; Zippel T; Wahnschaffe U; Bendfeldt K; Riecken EO; Ullrich R
AIDS; 1999 Dec; 13(18):2595-7. PubMed ID: 10630532
[No Abstract] [Full Text] [Related]
17. Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Gao W; Kageyama M; Inoue Y; Tadano J; Fukumoto K; Fukushima K; Yamasaki D; Nishimura A; Yoshikawa Y; Shibata N; Takada K
Biol Pharm Bull; 2003 Feb; 26(2):199-204. PubMed ID: 12576680
[TBL] [Abstract][Full Text] [Related]
18. The mechanism for differential effect of nelfinavir and indinavir on collagen metabolism in human skin fibroblasts.
Szoka L; Karna E; Andrulewicz-Botulinska E; Hlebowicz-Sarat K; Palka JA
Exp Dermatol; 2019 Jul; 28(7):845-853. PubMed ID: 31077466
[TBL] [Abstract][Full Text] [Related]
19. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
20. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
Eagling VA; Back DJ; Barry MG
Br J Clin Pharmacol; 1997 Aug; 44(2):190-4. PubMed ID: 9278209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
